Objectives. To characterise putative AmpC hyper-producing 3 rd generation cephalosporin-19 resistant E. coli from dairy farms and their phylogenetic relationships as well as to identify risk 20 factors for their presence; to assess evidence for their zoonotic transmission into the local 21 human population 22
Introduction 44
Escherichia coli typically produce a class 1 cephalosporinase, encoded by the ampC gene, 45 which is chromosomally located. Expression of ampC in wild-type cells is low and not enough 46 to confer clinically relevant resistance to β-lactam antibiotics. Many mutations, insertions and 47 gene duplication events have been shown to cause ampC hyper-expression, and this leads to 48 varying spectra of β-lactam resistance, dependent on the actual amount of AmpC produced. 1 
49
AmpC hyper-production was first seen in E. coli from human clinical samples in 1979, 2 and for 50 a period before the emergence of plasmid-mediated extended spectrum β-lactamases, AmpC 51 hyper-production was a dominant mechanism of 3 rd generation cephalosporin (3GC) 52 resistance in E. coli from humans. 1 This is no longer the case, however. For example, in a 53 recent survey of cefotaxime resistant (CTX-R) E. coli from urine collected from people living 54 in South West England, only 24/626 isolates (3.8%) were presumed to be AmpC hyper-55 producers because of their lack of horizontally acquired βlactamase genes; whole genome 56 sequencing (WGS) confirmed that 13/13 sequenced isolates had ampC promoter mutations 57 typical of AmpC hyper-producers. 3 58
AmpC is typical of class 1 enzymes in that it does not confer resistance to the 4 th generation 59 cephalosporins (4GC). 1 However, ampC structural variants of E. coli, expanding AmpC activity 60 to include, for example, cefepime, have been identified from humans 4-7 and cattle; 8 these are 61 dominated by isolates from the relatively less pathogenic phylogroup A, and particularly 62 ST88, 6, 8 probably because expanded-spectrum activity evolves from existing AmpC hyper-63 producers, of which ST88 isolates are particularly common. 9 64
We recently conducted a survey of 4594 samples collected from faecally contaminated sites 65 on 53 dairy farms in South West England. We identified 384 samples, collected across 47 66 farms, that were positive for the detectable growth of CTX-R E. coli isolates. 10 In an recent 67 paper, we reported that 566/1226 of these CTX-R E. coli isolates (from 186 samples from 38 68 farms) were PCR-negative for mobile cephalosporinases and so were presumed to be 69 chromosomal AmpC hyper-producers. 11 If this presumption was correct, AmpC hyper-production was the mechanism of resistance in 46.2% of CTX-R E. coli from dairy cattle in this 71 region of the UK. This figure is comparable with the 42.9% presumed AmpC hyper-producers 72 seen in CTX-R E. coli from dairy cattle in a recent nationwide Dutch study 12 and contrasts 73 with the 3.8% of AmpC hyper-producers seen in CTX-R isolates in our recent study of human 74 urinary E. coli. 3 75
One aim of the work reported here was to characterise putative AmpC hyper-producing E. coli 76 from our recent survey of dairy farms 10, 11 and to identify risk factors for the presence of AmpC 77 hyper-producers on these farms. Another aim was to investigate potential zoonotic 78 transmission of AmpC hyper-producers by using WGS-based phylogenetic analysis to 79 compare isolates from farms located within an approximately 50 x 50 km sub-region of the 80 study with human urinary E. coli collected in parallel from this same sub-region . 3 81 82
Materials and Methods 83
Bacterial isolates, identification and susceptibility testing 84
Isolates used in this study came from dairy farms located within a sub-region of the wider 85 study area. 10, 11 This region was chosen because it also included the locations of 146 GP 86 practices that submitted urine samples for processing at the Severn Pathology laboratory, as 87 described in a recently published survey of human urinary E. coli; 3 this laboratory was also the 88 source of the human urinary isolates used in the present study. Disc susceptibility testing and 89 microtiter MIC assays were performed and interpreted according to CLSI guidelines. 13 to prepare CA-MHB subcultures, which were incubated at 37°C until a 0.6-0.8 OD600 was 95 reached. Cells were pelleted by centrifugation (4000 rpm, 10 min; ALC, PK121R) and 96 resuspended in 1 mL of phosphate-buffered saline. The optical densities of all suspensions 97 were adjusted to 0.1 OD600. Aliquots of 180 µL of cell suspension were transferred to a black 98 flat-bottomed 96-well plate (Greiner Bio-one, Stonehouse, UK). Eight technical replicates for 99 each strain tested were in each column of the plate. The plate was transferred to a POLARstar 100 spectrophotometer (BMG Labtech) and incubated at 37°C. Hoescht dye (H33342, 25 µM in 101 water) was added to bacterial suspension of the plate using the plate-reader's auto-injector to 102
give a final concentration of 2.5 µM per well. Excitation and emission filters were set at 355 103 nm and 460 nm respectively. Readings were taken in intervals (cycles) separated by 150 104 seconds (s). Thirty-one cycles were run in total. A gain multiplier of 1300 was used. Results 105 were expressed as absolute values of fluorescence versus time. were stained with Instant Blue (Expedeon) for 5 min and de-stained in water. LC-MS/MS data 119 was collected as previously described. 17 The raw data files were processed and quantified 120 using Proteome Discoverer software v1.4 (Thermo Scientific) and searched against bacterial 121 genome and horizontally acquired resistance genes using as described previously. 18 Whole genome sequencing and analyses 123 WGS was performed by MicrobesNG (https://microbesng.uk/) on a HiSeq 2500 instrument 124 (Illumina, San Diego, CA, USA) using 2x250 bp paired end reads. Reads were trimmed using 125
Trimmomatic 19 and assembled into contigs using SPAdes 3.13.0 20 (https:// 126 http://cab.spbu.ru/software/spades/). Resistance genes, plasmid replicon types and sequence 127 types (according to the Achtman scheme 21 ) were assigned using the ResFinder, 22 128
PlasmidFinder, 23 and MLST 2.0 on the Center for Genomic Epidemiology 129 (http://www.genomicepidemiology.org/) platform. Contigs were annotated using Prokka 1.2. 24 130
Phylogenetic analysis 131
Sequence alignment and phylogenetic analysis was carried out on the Bioconda software 132 package 25 on the Cloud Infrastructure for Microbial Bioinformatics (CLIMB). 26 Sequences were 133 first aligned to a closed read reference sequence and analysed for SNP differences, whilst 134 omitting insertion and deletion elements, using the 'Snippy' alignment program. Alignment was 135 then focused on regions of the genome found across all isolates, using the Snippy-core 136 program, thus eliminating the complicating factors of insertions and deletions. 27 Aligned 137 sequences were then used to construct a maximum likelihood phylogenetic tree using RAxML, 138 utilising the GTRCAT model of rate heterogeneity and the software's autoMR and rapid 139 bootstrap to find the best-scoring maximum likelihood tree and including tree branch lengths, 140 defined as the number of base substitutions per site compared. 28, 29 Finally, phylogenetic trees 141 were illustrated using the web-based Microreact program. 30 142
Risk factor analysis 143
Multivariable, multilevel logistic regression analysis was performed to identify risk factors for 144 the presence of AmpC hyper-producers in samples collected from farms. Positivity for AmpC 145 hyper-producing E. coli in a sample was defined by the growth of E. coli on cefotaxime agar 146 which were PCR-negative for known horizontally-acquired cefotaxime resistance genes. 11 The 147 risk factor analysis methodology used has been described previously, including the use of a 148 novel method using a logistic link function to account for measurement error. 10 149 150
Results and Discussion 151
Confirmation of AmpC hyper-production and identification of porin loss and marR mutations 152 in E. coli from dairy farms 153
In order to further investigate putative AmpC hyper-producing E. coli isolates from dairy farms 154 identified in our recent surveillance study, 10,11 antibiograms were determined for one putative 155
AmpC hyper-producing isolate from each of 5 randomly selected farms. All isolates presented 156 a typical AmpC-hyper-producing phenotype: resistance to ampicillin and cefalexin, and non-157 susceptibility to cefotaxime and ceftazidime. The isolate from Farm 1 was clearly different from 158 the others -resistant to ceftazidime, cefotaxime, ceftriaxone, and non-susceptible to 159 cefoperazone and cefepime based on disc testing ( Table 1) . MIC testing confirmed this 160 difference for ceftazidime and cefepime, extending it into 3GC/4GCs licenced for use in cattle 161 in the UK ( Table 2) . Relative to a non-AmpC hyper-producing control E. coli 17, all putative 162
AmpC hyper-producers were non-susceptible to ceftazidime and ceftiofur (a 3GC used on 163 several study farms during the period of sample collection) but not generally cefoperazone, 164 cefepime or cefquinome (a 4GC used on some study farms during the period of sample 165 collection). The MICs of the 4GCs cefepime and cefquinome were, respectively, 6 and 7 166 doublings higher against the isolate from Farm 1 than against the control isolate, and 5 167 doublings higher for each drug than against the isolate from Farm 2 ( Table 2) . 168
Using LC-MS/MS proteomics, AmpC hyper-production was confirmed in the isolate from Farm 169 1, relative to a control E. coli 17, but AmpC production in this isolate was not more than in the 170 other 4 confirmed AmpC hyper-producing isolates ( Table 3) . Sequencing the ampC promoter 171 region revealed that all 5 AmpC hyper-producers had the same mutations, relative to the E. 172 coli 17 control (Figure 1) , which have previously been shown to cause ampC hyper-173 expression. 1 Proteomics showed that, unlike the other 4 AmpC hyper-producers, the 174 cefepime-resistant isolate from Farm 1 did not produce the OmpF porin (Table 3) , and WGS 175 revealed a loss of function mutation in ompF caused by the insertion of IS4 at nucleotide 625. 176
OmpF porin loss did not noticeably affect envelope permeability in the Farm 1 isolate relative 177 to the other 4 isolates or the E. coli 17 control (Figure 2) . Indeed, the isolate from Farm 4 had 178 markedly reduced permeability, reminiscent of an efflux hyper-production phenotype (constant 179 reduced accumulation of the fluorescent dye; Figure 2 ) and yet it was not resistant to cefepime 180 ( resistant to these agents, were shown by WGS to carry specific mobile resistant genes (Table  186 1). Interestingly, the Farm 4 isolate was cefoperazone-resistant ( Table 2) . It would seem, 187 therefore, that a combination of AmpC plus AcrAB-TolC hyper-production and/or OmpF down 188 regulation leads to cefoperazone resistance in E. coli. Cefoperazone has been, albeit rarely, 189 used as a therapy for mastitis in dairy cows in the UK. WGS showed that isolate Farm-WT had an identical ampC open reading frame and promoter 199 sequence to that carried by the isolate from Farm 1, but without the single mutation predicted to cause expanded-spectrum AmpC activity. We therefore selected a mutant (Farm-WT-M1) 201 using ceftazidime at its agar dilution MIC (8 mg/L) using Muller Hinton Agar. The mutant did 202 not have altered production of key resistance proteins relative to its parent, Farm-WT (Table  203 3). Sequencing of the ampC gene from Farm-WT-M1 revealed an identical His296Pro 204 mutation to that seen in the isolate from Farm 1, and the mutant had the same expanded-205 spectrum antibiogram as the isolate from Farm 1 ( Table 2 ). Since Farm-WT-M1, like its parent, 206 has wild type ompF, this confirmed that the insertional inactivation of ompF seen in the isolate 207 from Farm 1 had little impact on the MICs of expanded-spectrum cephalosporins in the 208 presence of an expanded-spectrum AmpC variant ( Table 2) . 209
We next performed WGS analysis of putative AmpC hyper-producers identified in our 210 molecular epidemiology survey 11 from 25 farms across the core portion of our study area; 10 211 this area also included the locations of 146 GP practices involved in a parallel survey of human 212 urinary E. coli. 3 All 25 representative isolates had the same ampC promoter mutation reported 213 above (Figure 1) . This isolate had the same expanded spectrum antibiogram as that from Farm 1 ( Table 2) . 218
These 2 isolates, from farms 40 km apart, were both ST641 and only 64 SNPs apart in the 219 core genome, based on phylogenetic analysis (Figure 3) . This can be compared with SNP 220 distances of 1-13 SNPs across 6 sequenced isolates collected from Farm 1 over a 12-month 221 period. Interestingly, the ompF porin gene was intact in the isolate from Farm 22 so ompF 222 disruption must have occurred following separation of the isolates. Measurement of MICs 223 against the isolates provided further evidence that loss of ompF was not important for 224 3GC/4GC resistance conferred by the expanded-spectrum AmpC in the isolate from Farm 1 225 (Table 2) . Interestingly, another ST641 isolate, from Farm 7 (which is 7 km from Farm 1), had 226 1520 SNPs different from the isolate from Farm 1 (Figure 3) and did not have the expanded-227 spectrum AmpC mutation or an ompF mutation; this isolate shared these properties with the 228 isolate from Farm 14, which was only 35 SNPs (Figure 3) but 45 km away from Farm 7. 229
Risk factor analysis 230
The data presented above, when considered in conjunction with that in our recent survey, 11 231
show that 46.2% of CTX-R E. coli from dairy cattle across the 53 farms enrolled in our study 232
were AmpC hyper-producers. This compares with 52.9% that were CTX-M producers, the 233 remainder being plasmid AmpC producers. 11 Accordingly, attempts to reduce the prevalence 234 of 3GC resistance on dairy farms must address the specific factors that are driving the 235 accumulation of AmpC hyper-producers. In order to identify factors associated with an 236 increased risk of finding CTX-R, AmpC hyper-producing E. coli in a sample from farms in our 237 study, we performed risk factor analyses. Three farm-level fixed effects and 2 sample-level 238 fixed effects were identified as important ( Table 5 ). As seen with our risk factor analysis for 239 blaCTX-M-positive CTX-R E. coli on the same farms, 10 samples collected from the environment 240 of young calves were much more likely to be positive for AmpC hyper-producing E. coli 241 (p<0.001) and samples collected from pastureland, including publicly accessible sites, were 242 much less likely to be positive (p=0.005). We found no association between cephalosporin 243 useincluding 3GC useand increased risk of finding AmpC hyper-producers. Interestingly, 244 however, the total usage of amoxicillin-clavulanate was associated with a higher risk of finding 245
AmpC hyper-producing E. coli on a farm (p=0.001). This association can be explained by 246 direct selection since AmpC hyper-production confers amoxicillin-clavulanate resistance in E. 247 coli. 1 This finding is important because amoxicillin-clavulanate is not currently identified as a 248 highest-priority critically important antimicrobial (HP-CIA) by the World Health Organisation, 32 249 and, whilst great strides have been made within the UK farming industry to reduce antibiotic 250 use, 33 there is a particular focus on reducing HP-CIA, e.g. 3GC use. The associations 251 identified in our risk factor analysis suggest that reducing HP-CIAs without also reducing 252 amoxicillin-clavulanate use may not impact on the prevalence of CTX-R, AmpC hyper-253 producing E. coli on farms. Indeed, a bigger concern is that reducing 3GC use on farms may drive up amoxicillin-clavulanate use providing additional co-selective pressure for 3GC-255 resistant E. coli. 256
A final observation from this analysis is that average monthly temperature, which was 257 identified as a strong risk factor for finding blaCTX-M-positive E. coli in this same survey of dairy 258 farms, 10 was not identified as a risk factor for finding AmpC hyper-producing E. coli. This may 259 be an issue of power, but the numbers of blaCTX-M E. coli positive and AmpC hyper-producing 260 E. coli positive samples in the survey were similar (224 vs 186). It may be hypothesised, 261 therefore, that carriage of (i.e. because of some fitness cost) or transmission rate for the 262 horizontally acquired blaCTX-M is specifically affected by temperature, whereas the presence of 263 chromosomal mutations in the ampC promoter leading to AmpC hyper-production is not. with almost double the amont of AmpC in UTI-8 than in UTI-9 (Table 3 ). There were 9 different 271 ampC promoter types seen across the 20 AmpC hyper-producing human isolates, though 272 11/20 isolates carried the same promoter mutation seen in all 25 farm isolates, including UTI-273 8 and UTI-9, though UTI-8 also has an attenuator mutation at +37, which probablhy explain 274 the higher level of AmpC seen in UTI-8 that UTI-9 (Figure 4, Table 3 ). None of the human 275 isolates had mutations suggestive of an expanded spectrum AmpC variant, which was 276 confirmed phenotypically using cefepime disc susceptibility testing. 277
Our final aim was to identify if there was any evidence of sharing AmpC hyper-producing E. 278 coli between humans and cattle, since dominance of ST88 has previously been reported in 279 humans in Northern Europe 9 and since we found an over-representation of ST88 on our farms 280 (Table 4) . A phylogenetic tree drawn based on core genome comparison showed that the 281 cattle and human isolates were intermixed only to a small extent, with only one human ST88 282 isolate found (Figure 3) . Importantly, all 10 ST88 cattle isolates were 15 or fewer SNPs apart, 283
suggesting very recent farm-to-farm transmission; the human ST88 isolate (UTI-19) was, at 284 its closest distance, 1279 SNPs different from the cattle isolates. The 2 other examples where 285 isolates from the same ST were found in farm and human samples gave the same story 286 (Figure 3) : for ST75, the 2 human isolates (UTI-2 and UTI-15) were 60 SNPs apart, but the 287 cattle isolate (Farm-6) was 1972 SNPs different at best. For ST23, the human and cattle 288 isolates (UTI-13 and Farm-8, respectively) were 2754 SNPs different. Otherwise, there was 289 no ST sharing, and all cattle isolates fell into phylogroups B1 and C (Table 4) , with 8/20 human 290 isolates falling into the highly pathogenic phylogroup B2, including a cluster of ST73 isolates 291 of which 3 were only 2 SNPs apart. 292
Conclusions 293
AmpC hyper-production is a remarkably common mechanism of 3GC resistance in E. coli from 294 dairy farms in our study -similar to a national survey in The Netherlands. 12 We have shown 295 an association between amoxicillin-clavulanate use and the risk of finding AmpC hyper-296 producers on dairy farms and would caution against a blanket switch from 3/4GCs to 297 amoxicillin-clavulanate in response to justifiable action to reduce HP-CIA use. However, our 298 comparison between AmpC hyper-producing farm and human urinary E. coli in the same 299 region provided no evidence of local sharing of AmpC hyper-producers between farms and 300 the local human population. Accordingly, whilst reducing the on-farm prevalence of AmpC 301 hyper-producing E. coli should be an important aim, the primary reason for achieving this 302 would be to reduce the likelihood of difficult to treat infections in cattle rather than because of 303 any direct zoonotic threat. with the dye is presented relative to that in the control E. coli strain EC17 after each cycle. 517
Each line shows mean data for 3 biological replicates with 8 technical replicates in each.
518
Error bars define the standard error of the mean. The phylogenetic tree was illustrated using the Microreact program using a maximum likelihood tree generated from core genome alignments as described in Materials and Methods. Isolates are coloured green (human urinary) and blue (farm). The ST88 finished reference genome used to generate the alignments is noted in black. Modified residues relative to the transcriptional start site are noted and the novel promoter created is annotated.
